Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79915.510.0938%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Voyager Therapeutics Inc

VYGRNASDAQ
Trade with Public
Trade with Public
$3.51
0.133.85%
At close: Sep 4, 5:00 PM EST
$3.50
-0.01-0.28%
After Hours: Sep 4, 4:39 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Voyager Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Voyager Therapeutics (VYGR).

Price Target Range — 10 Quarters

Analyst Consensus — 9 Analysts

9Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$16Upside to Avg. PT+354.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 10, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$25
Mar 17, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Voyager Therapeutics, Lowers Price Target to $25

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Voyager Therapeutics (NASDAQ:VYGR) with a Buy and lowers the price target from $30 to $25.
Benzinga Newsdesk

Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.
Vandana Singh

PRO
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Voyager Therapeutics, Lowers Price Target to $8

Wedbush analyst Yun Zhong maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and lowers the price target from $9 to $8.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved